42O Biomarker Analysis from KAITLIN, a Randomised Phase III Study of Adjuvant Trastuzumab Emtansine (TDM-1; K) Plus Pertuzumab (P) Versus Trastuzumab (H) Plus Taxane (T) Plus P after Anthracyclines (AC) for High-Risk HER2-positive Early Breast Cancer (EBC)
ANNALS OF ONCOLOGY（2021）
Key words
Trastuzumab,Breast Cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined